1. Sato T, Kusaka S, Hashida N, et al. Comprehensive gene-expression profile in murine oxygen-induced retinopathy. Br J Ophthalmol. 2009. 93:96–103.
2. van Wijngaarden P, Brereton HM, Gibbins IL, et al. Kinetics of strain-dependent differential gene expression in oxygen-induced retinopathy in the rat. Exp Eye Res. 2007. 85:508–517.
3. van Wijngaarden P, Brereton HM, Coster DJ, Williams KA. Hereditary influences in oxygen-induced retinopathy in the rat. Doc Ophthalmol. 2010. 120:87–97.
4. van Wijngaarden P, Brereton HM, Coster DJ, Williams KA. Stability of housekeeping gene expression in the rat retina during exposure to cyclic hyperoxia. Mol Vis. 2007. 13:1508–1515.
5. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003. 121:1684–1694.
6. Chan-Ling T, Tout S, Holländer H, Stone J. Vascular changes and their mechanisms in the feline model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1992. 33:2128–2147.
7. Zhang W, Ito Y, Berlin E, et al. Role of hypoxia during normal retinal vessel development and in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2003. 44:3119–3123.
8. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995. 15(7 Pt 1):4738–4747.
9. Reynaud X, Dorey CK. Extraretinal neovascularization induced by hypoxic episodes in the neonatal rat. Invest Ophthalmol Vis Sci. 1994. 35:3169–3177.
10. Min XJ, Zhou QJ, Liu T, et al. Expression of mouse telomerase reverse transcription in a mouse model of oxygen-induced retinopathy. Zhonghua Yan Ke Za Zhi. 2009. 45:199–205.
11. Budd SJ, Hartnett ME. Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity. Arch Ophthalmol. 2010. 128:589–595.
12. Zhang ZH, Jiang L, Qiao LX. Expression of mRNA of vascular endothelial growth factor in a rat model of hyperoxia-induced retinopathy. Zhongguo Dang Dai Er Ke Za Zhi. 2007. 9:371–374.
13. Kim YH, Chung IY, Choi MY, et al. Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia. Neurobiol Dis. 2007. 26:569–576.
14. Kim YH, Kim YS, Kang SS, et al. Expression of 14-3-3 zeta and interaction with protein kinase C in the rat retina in early diabetes. Diabetologia. 2005. 48:1411–1415.
15. Noh HS, Lee HP, Kim DW, et al. A cDNA microarray analysis of gene expression profiles in rat hippocampus following a ketogenic diet. Brain Res Mol Brain Res. 2004. 129:80–87.
16. Simons BD, Flynn JT. Retinopathy of prematurity and associated factors. Int Ophthalmol Clin. 1999. 39:29–48.
17. Madan A, Penn JS. Animal models of oxygen-induced retinopathy. Front Biosci. 2003. 8:d1030–d1043.
18. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000. 156:697–707.
19. Morita M, Ohneda O, Yamashita T, et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003. 22:1134–1146.
20. Sarlos S, Rizkalla B, Moravski CJ, et al. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol. 2003. 163:879–887.
21. Byfield G, Budd S, Hartnett ME. The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model. Invest Ophthalmol Vis Sci. 2009. 50:3360–3365.